discovered, validated and profiled using diseased and normal human cells as the discovery platform technologies
This is a new type of epithelial sodium channel (ENaC) inhibitor that works through CFTR correction/ activation to lower ENaC cell surface expression. It is viable for all forms of polycystic kidney disease (PKD), cystic fibrosis (CF) , salt-sensitive hypertension and niche renal hypertensive disorders.
Hit-to-lead stimulator of interferon genes (STING) inhibitors. Viable for niche autoimmune diseases of the lung, kidney and skin, the “lupus” umbrella of autoimmune diseases and neurodegenerative diseases with chronic neuroinflammation component.
These are lead and back-up lead small molecules, respectively, that stimulate human fat cells to produce and secrete the native adiponectin, a beneficial adipokine lost in diabetes and obesity. Viable for hypertriglyceridemia and for kidney injury and cardiac injury as secondary indications of diabetes and obesity.
AeroNeph Therapeutics, Inc. has emerged from the humanized drug discovery approach of its parent company, DiscoveryBioMed, Inc., and is continuing to develop lead and hit-to-lead small molecules for specific human disease indications and for human taste marketplaces.